Shots:

• Bausch + Lomb (Bausch Health’s subsidiary) acquires US commercial rights from Eton Pharmaceuticals for its EM-100- has been evaluated in P-III study vs PBO in patients with ocular itching associated with allergic conjunctivitis- demonstrated no AEs and non-inferiority data
• The focus of the agreement is to strengthen Bausch’s portfolio of ophthalmology with the expansion of Eton Pharmaceuticals'EM-100 sales
• Eton Pharmaceuticals' EM-100 is a novel OTC preservative-free formulated eye drop used to treat itchy eyes associated with allergies with awaited FDA approval

Ref: Bausch Health | Image: USA today